Paul Roux

Dr. Paul Roux

Université Versailles Saint Quentin, Versailles, Île-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2016 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
EBEwa Bulzacka
Ewa Bulzacka
LBLaurent Boyer
Laurent Boyer
FSFranck Schürhoff
Franck Schürhoff
OGOphélia Godin
Ophélia Godin
FBFabrice Berna
Fabrice Berna
TGthe FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group
the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group
Objectives: Inflammation, measured by abnormal blood C-reactive protein (CRP) level, has been described in schizophrenia (SZ), being inconsistently related to impaired cognitive functions. The aim of the present study is to investigate cognitive impairment associated with abnormal CRP levels in a large multi-centric sample of community-dwelling SZ patients, using a comprehensive neuropsychological battery. Method: Three hundred sixty-nine community-dwelling stable SZ subjects (76.2% men, mean age 32.7 y) were included and tested with a comprehensive battery of neuropsychological tests. Abnormal CRP level was defined as >3mg/L. Results: Multiple factor analysis revealed that abnormal CRP levels, found in 104 patients (28.2%), were associated with impaired General Intellectual Ability and Abstract Reasoning (aOR = 0.56, 95% CI 0.35–0.90, P = .014), independently of age, sex, education level, psychotic symptomatology, treatments, and addiction comorbidities. Abnormal CRP levels were also associated with the decline of all components of working memory (respectively effect size [ES] = 0.25, P = .033; ES = 0.27, P = .04; ES = 0.33, P = .006; and ES = 0.38, P = .004) and a wide range of other impaired cognitive functions, including memory (ES = 0.26, P = .026), learning abilities (ES = 0.28, P = .035), semantic memory (ES = 0.26, P = .026), mental flexibility (ES = 0.26, P = .044), visual attention (ES = 0.23, P = .004) and speed of processing (ES = 0.23, P = .043). Conclusion: Our results suggest that abnormal CRP level is associated with cognitive impairment in SZ. Evaluating the effectiveness of neuroprotective anti-inflammatory strategies is needed in order to prevent cognitive impairment in SZ.

7 January 2020 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
NCNathalie Coulon
Nathalie Coulon
OGOphélia Godin
Ophélia Godin
EBEwa Bulzacka
Ewa Bulzacka
CDCaroline Dubertret
Caroline Dubertret
JMJasmina Mallet
Jasmina Mallet
FSFranck Schürhoff
Franck Schürhoff
Objective: To compare the clinical symptomatology in patients with Early‐Onset Schizophrenia (EOS, N = 176), especially the subgroup Very Early Onset Schizophrenia (VEOS) and Adult Onset Schizophrenia (AOS, N = 551).Method: In a large French multicentric sample, 727 stable schizophrenia patients, classified by age at onset of the disorder, were assessed using standardized and extensive clinical and neuropsychological batteries: AOS with onset ≥ 18 years and EOS with onset < 18 years (including 22 VEOS < 13 years).Results: The importance of better diagnosing EOS group, and in particularly VEOS, appeared in a longer DUP Duration of Untreated Psychosis (respectively, 2.6 years ± 4.1 and 8.1 years ± 5.7 vs. 1.0 years ± 2.5), more severe symptomatology (PANSS Positive And Negative Syndrome Scale scores), and lower educational level than the AOS group. In addition, the VEOS subgroup had a more frequent childhood history of learning disabilities and lower prevalence of right‐handedness quotient than the AOS.Conclusion: The study demonstrates the existence of an increased gradient of clinical severity from AOS to VEOS. In order to improve the prognosis of the early forms of schizophrenia and to reduce the DUP, clinicians need to pay attention to the prodromal manifestations of the disease.

1 July 2021 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
MRMartin Rouy
Martin Rouy
PSPauline Saliou
Pauline Saliou
LNLadislas Nalborczyk
Ladislas Nalborczyk
MPMichael Pereira
Michael Pereira
Paul RouxPaul Roux
Paul Roux
NFNathan Faivre
Nathan Faivre

1 December 2017 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
BEBruno Etain
Bruno Etain
MLM. Lajnef
M. Lajnef
CHC. Henry
C. Henry
VAV. Aubin
V. Aubin
JAJ.M. Azorin
J.M. Azorin
LAL. Albertini
L. Albertini

1 March 2017 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
Paul RouxPaul Roux
Paul Roux
ARAurélie Raust
Aurélie Raust
ACAnne Sophie Cannavo
Anne Sophie Cannavo
VAValérie Aubin
Valérie Aubin
Bruno AouizerateBruno Aouizerate
Bruno Aouizerate
CPChristine Passerieux
Christine Passerieux

1 October 2010 in Neuropsychologia
Verified
Journal Article
Closed access
Paul RouxPaul Roux
Paul Roux
ACA. Christophe
A. Christophe
CPC. Passerieux
C. Passerieux